These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38164271)

  • 1. IGFBP5, as a Prognostic Indicator Promotes Tumor Progression and Correlates with Immune Microenvironment in Glioma.
    Lin J; Huang G; Zeng Q; Zhang R; Lin Y; Li Y; Huang B; Pan H
    J Cancer; 2024; 15(1):232-250. PubMed ID: 38164271
    [No Abstract]   [Full Text] [Related]  

  • 2. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
    Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
    Front Genet; 2022; 13():1053263. PubMed ID: 36712869
    [No Abstract]   [Full Text] [Related]  

  • 5. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
    Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
    Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased UBD Is a Potential Diagnostic and Prognostic Biomarker in Glioma.
    Wu T; Du M; Zeng L; Wang H; Li X
    Environ Toxicol; 2024 Aug; ():. PubMed ID: 39155575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCAPG as a Novel Prognostic Biomarker in Glioma.
    Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
    Front Oncol; 2022; 12():831438. PubMed ID: 35280743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
    Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
    Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
    Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
    Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
    Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
    Front Genet; 2021; 12():718717. PubMed ID: 34925438
    [No Abstract]   [Full Text] [Related]  

  • 12. Pan-cancer analysis of the disulfidptosis-related gene
    Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
    Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
    Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
    Front Oncol; 2022; 12():889351. PubMed ID: 36033495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The N6-Methylandenosine-Related Gene
    Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
    Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
    Zhang M; Wang X; Chen X; Zhang Q; Hong J
    Front Genet; 2020; 11():363. PubMed ID: 32351547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in Glioblastoma multiforme cells.
    Dong C; Zhang J; Fang S; Liu F
    Cell Div; 2020; 15():4. PubMed ID: 32127912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analyses and Experiments Confirmed IGFBP5 as a Prognostic Predictor Based on an Aging-genomic Landscape Analysis of Ovarian Cancer.
    Fan TY; Xu LL; Zhang HF; Peng J; Liu D; Zou WD; Feng WJ; Qin M; Zhang J; Li H; Li YK
    Curr Cancer Drug Targets; 2024; 24(7):760-778. PubMed ID: 38018207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.